RxDoctor Payments Data

Anna Claugus, MD

Family Medicine · Mooresville, NCNPI 1710278262

Payments from drug & device makers

$2,719in general payments, 2019–2025

Across 153 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$591
  • AbbVie$259
  • AstraZeneca$187
  • Pfizer$179
  • Amgen$168
  • Astellas Pharma US Inc$154
  • plus $1K from 35 others

What the payments were for

  • Food & beverage$2,719100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,719 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$75,371
Medicare patients
187
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$60,269
OzempicSemaglutide35$58,358
MounjaroTirzepatide50$55,857
XifaxanRifaximin11$34,311
JardianceEmpagliflozin29$34,084
RybelsusSemaglutide11$24,617
JanuviaSitagliptin Phosphate15$24,079
XareltoRivaroxaban13$19,394
Repatha SureclickEvolocumab17$14,805
Spiriva HandihalerTiotropium Bromide15$11,687
PremarinEstrogens, Conjugated14$6,944
Sumatriptan Succinate28$2,264
Rosuvastatin Calcium209$2,054
Levothyroxine Sodium219$1,843
Atorvastatin Calcium265$1,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$591$82,97446 claims
PfizerEliquis, Premarin$179$67,21364 claims
Lilly USA, LLCMounjaro$112$55,85750 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$43$34,31111 claims
Boehringer IngelheimJardiance$66$34,08429 claims
MerckJanuvia$47$24,07915 claims
Johnson & JohnsonXarelto$37$19,39413 claims
AbbVieSynthroid$259$1,54033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →